Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term ...

The decision follows the initial approval granted in September 2023, which covered patients aged five years and above.

The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and ...

Patients with atopic dermatitis experienced improvements in severity with 16 weeks of tralokinumab despite the number of ...

This LSPN panel features experts from Maiwald, Regeneron, Vertex Pharmaceuticals, and Taylor Wessing discussing the impact of ...

The deal’s structure allows shareholders to benefit from potential future income streams, with payments linked to performance ...

When it comes to groundbreaking biotech advancements, Eric Faw Intellia is a name you might wanna keep an eye on. This ...

Sanofi is a high-quality, undervalued pharma giant trading near 10x P/E. Click here to read more about SNY stock and why it ...

CT is your last chance to file a claim with 23andMe for a 2023 data breach that may have compromised your genetic data.

Wall Street trading got off to a mixed start on Tuesday as market participants digested key inflation data and Q2 bank ...

OraSure’s board is said to have rejected the proposal without entering discussions. This is Zwanziger’s second attempt to ...

Major indices closed higher on Monday as traders continued to monitor trade headlines ahead of key inflation data and the ...